SEPN Surges on Revenue Windfall, But Will Pipeline Deliver

Septerna (SEPN) reported fiscal 2025 Q4 earnings on March 9, 2026, with a significant revenue surge and reduced losses. The company’s GAAP EPS of -$0.24 beat estimates by $0.02, while revenue of $24.1M exceeded expectations by $8.54M. Guidance highlighted pipeline advancements, including Phase 2b trials for SEP-631 by late 2026 and a cash runway extending through 2029.

Revenue

Septerna’s total revenue surged 11,276.4% to $24.12 million in 2025 Q4, jumping from $212,000 in the prior-year period. This extraordinary growth was driven by non-recurring amortization from Novo Nordisk’s $195M upfront payment, which contributed $26.8M to 2025 revenue.

Earnings/Net Income

The company narrowed its per-share loss to $0.24 in 2025 Q4 from $0.47 in 2024 Q4, reflecting a 48.5% improvement. Net losses also decreased to $10.74 million from $20.67 million, a 48.0% reduction. The EPS improvement indicates progress in cost management and operational efficiency.

Post-Earnings Price Action Review

The strategy of buying Septerna shares after its revenue raised quarter-over-quarter on the report date and holding for 30 days delivered strong returns over three years, achieving an overall return of 41.80% and a CAGR of 29.64%. However, the strategy faced high volatility, with a maximum drawdown of 84.64% and a Sharpe ratio of 0.25, suggesting moderate risk-adjusted performance. Despite outperforming the 16.11% benchmark, the high drawdown underscores the stock’s speculative nature.

CEO Commentary

Jeffrey Finer highlighted progress in Septerna’s pipeline, including positive Phase 1 results for SEP-631, which validates the Native Complex Platform®. The company’s $548.7M cash reserves, sufficient through 2029, support R&D initiatives, including SEP-479’s Phase 1 trials in H1 2026 and exploration of MRGPRX2-driven diseases.

Guidance

Septerna plans to initiate a Phase 2b trial for SEP-631 in chronic spontaneous urticaria by late 2026 and a Phase 1 trial for SEP-479 in H1 2026. The company expects continued revenue from research services with Novo Nordisk and anticipates advancing discovery-stage programs.

Additional News

Recent updates include Septerna’s CEO emphasizing the Native Complex Platform’s role in developing oral small molecules for GPCRs, positioning the company to advance SEP-631 into Phase 2b trials. The company’s robust cash reserves and extended runway through 2029 underscore its focus on R&D. Strategic priorities also include TSHR NAM program development and MRGPRX2-driven disease exploration, reflecting confidence in therapeutic innovation.